Skip to content
The Policy VaultThe Policy Vault

Inrebic (fedratinib capsules)Cigna

Myeloid or Lymphoid Neoplasms with eosinophilia and JAK2 rearrangement

Initial criteria

  • Patient is age ≥ 18 years AND
  • Patient has eosinophilia AND
  • Tumor has a Janus Associated Kinase 2 (JAK2) rearrangement

Approval duration

1 year